Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.

Ambrx Biopharma Inc.

Infinimmune develops drugs from complete human antibodies. The therapeutic pipeline is built on antibodies produced by human immune systems, displaying a distinct approach compared to model organisms.

Infinimmune

Ambrx develops enhanced antibody-drug conjugates and employs expanded genetic code technology for potential cancer treatments. It focuses on precision biologics innovation.

Metric
Company Name	Ambrx Biopharma Inc.	Infinimmune
Symbol	AMAM
MSH ID	COM:AMBRX	COM:INFINIMMUNE
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	US	US
Stage
Employee Count	87
Website	ambrx.com	infinimmune.com
LinkedIn		infinimmune
Founders

Metric
Market Cap	1.77B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	7.40M
Revenue (LTM)
Revenue (NTM)
Gross Profit	7.40M
EBITDA	-55.79M
Operating Income	-57.08M
Net Income	-78.00M
EPS	-2.02
Diluted EPS	-2.02
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	1
Operating Profit Margin	-20.17
EBITDA Margin	-7.54
Net Profit Margin	-20.14
Return on Equity	-0.35
Return on Assets	-0.26
Return on Capital Employed	-0.27

COM:AMBRX

Ambrx

Last Close

27.98

06/03 21:00

Market Cap

1.77B

Beta: -

Volume Today

1.42M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-24.93
P/B Ratio	7.14
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	514.40
EV Multiple	-28.35

Metric
Days Sales Outstanding	249.73
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover	0.01

Metric
Operating Cash Flow	-68.67M
Free Cash Flow	-69.73M
Cash Flow to Debt	-5.48
Operating Cash Flow/Sales	-16.75
Free Cash Flow Yield	-0.03

Metric
Cash & Equivalents	55.61M
Accounts Receivable	863K
Inventory	3.73M
Goodwill
Debt to Capitalization	0.04
Debt to Assets	0.04
Current Ratio	12.80
Quick Ratio	12.46

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	3.14
R&D to Revenue	14.71
SG&A to Revenue	7.83